Pharmacogenomic studies have shown that drug metabolism in Mexican-Hispanic population can be influenced by its genetic makeup. When clinical studies are multicentric, Mexican population must be included. If Mexican patients are not included in the clinical trials: New Molecule Committee will request pharmacokinetic studies for evidence concluding no significant differences in safety or efficacy in Mexicans.